Drugs / C7R-EBV T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04664179 | Oct 2022 → Nov 2027 expected | Hodgkins lymphoma, non-Hodgkin lymphoma | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C7R-EBV T cells | “The purpose of this study is to find the largest safe dose of C7R-EBV T cells, and additionally to evaluate how long they can be detected in the blood and what affect they have...” NCT04664179 ↗ |
| Route | Intravenous | “injection of C7R EBV T cells into the vein through an IV line” NCT04664179 ↗ |